Our Investors

Strategic Investor – Pharco Pharmaceuticals

Pharco Pharmaceuticals is the mother company of Pharco group, founded by Dr. Hassan Abbas Helmy in 1983. Nine health care companies are operating in the pharmaceutical field for development, manufacturing, marketing, distributing and exporting of a comprehensive array of generics and branded generic drugs under the name of Pharco, along with a rising number of licensed pharmaceutical products.

Pharco is the largest manufacturer of pharmaceuticals in the MENA region, focused on research, formulation, manufacturing and commercialization of pharmaceutical products. Today Pharco employs over 8,000 employees, and has over 630M packs produced in the year 2016 — ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 47 countries around the world. Pharco works towards one goal: To provide highly effective and safe pharmaceutical products to patients at an affordable price.

Currently Dr. Sherine Hassan Abbas Helmy (Vice President of Pharco Corporation) is leading the organization. Dr Helmy sits on the Naia Limited Board of Directors.

Strategic Investor – Cedars-Sinai

Led by physicians who pioneered gastrointestinal endoscopy, Cedars-Sinai provides virtually every known gastroenterologic procedure and treatment for digestive diseases and disorders. With inpatient and outpatient programs and state-of-the-art technology, specialized and internationally renowned physicians, and a body of research, clinical expertise and results, the Cedars-Sinai Digestive Disease team treats all disorders with skill and experience.

Cedars-Sinai’s GI Motility Program is unique among motility centers because it treats almost all GI motility problems. They focus on the diagnosis and treatment of these digestive tract problems. Their program offers the most advanced diagnosis and treatment methods and is recognized throughout the world for their latest research discoveries, which are already being used to help patients.

Naia Rare Diseases lead program, NB 1001, is based on clinical research licensed from Cedars-Sinai and based on work published by Mark Pimentel MD FRCPC. Dr Pimentel is chairman of Naia’s board of scientific and clinical advisors and professor of medicine and director of the gastrointestinal motility program and laboratory at Cedars-Sinai Medical Center.

Private Investors

Naia Rare Diseases also has Private Investors with successful track records of investments in the pharmaceutical industry.

Contact us for further information